Published in Medical Letter on the CDC and FDA, August 16th, 2009
The global pain management market continued to demonstrate strong growth in 2007, despite patent expiries of leading products and strong generic competition. The NSAIDs segment of the market has overcome the impact of an FDA-imposed black box warning in 2005, however the local anesthetics market is facing significant generic penetration as the FDA has relaxed the requirements for the approval of the generic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA